Each year, 132,000 new cases of melanoma are diagnosed worldwide. In the United States, where its the fifth most common cancer, 96,480 new melanoma cases and 7,230 deaths are expected in 2019, according to the National Cancer Institute.
The research community is playing a vitally important role to reduce these numbers and improve outcomes.
The tools and platforms Elsevier provides to help researchers analyze and evaluate large volumes of data give us a bird’s eye view on what research institutions worldwide are doing in the fight against melanoma. We used that data to examine which institutions are currently leading charge and how they are creating their breakthroughs.
Our analysis of the top 50 institutions publishing melanoma research around the world finds that over the past 6 years, the research institutions that collaborate internationally the most typically have the greatest impact in melanoma research. We applaud these institutions.
We also know that for many, collaboration is something that happens organically based on who you know, not necessarily who is the best partner for your specific research needs. Elsevier is committed to playing its part in enabling collaboration around the world and supporting researchers and clinicians in their quest to minimize the devastating impact melanoma has on so many lives.
Download the report
Melanoma Research Insights: Impact, Trends, Opportunities. This analysis explores international trends in melanoma research.
- How novel melanoma treatments are improving outcomes for patients (Elsevier Connect)
- Via Oncology. Powering the cancer network of the future
- Outward looking UK scientists among global leaders in the fight against melanoma (PharmaTimes)
- Did you know immunotherapy is the most prominent topic in melanoma research globally? (Health Europa)
- Top international collaborators make more impact in the fight against melanoma (Wellbeing News)
- Report reveals immunotherapy is the most prominent topic in melanoma research globally (Elsevier's press release)